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Detailed characterisation of raw LAMV samples and methods development for 
process analytics (for quantitative and qualitative assessments). 
Isolation of stable Form I and improvement of particle properties.
Solubility/MSZW determination of anti-solvent system for Lamivudine and 
evaluation of process feasibility (small scale development and assessment) 
Obtain stable Form I Lamivudine with improved particle properties through 
crystal habit modification 
Demonstration of crystallisation of modified stable Form I Lamivudine from batch 
to a continuous platform 










Solubility Curve for Form I
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Solubility Curve for Form I
• As with the solubility curve it can be seen from the 
supersaturation profiles that the addition of 
antisolvent drives the system into a significantly 
supersaturated state.
• With a maximum possible supersaturation of 3.5 
and a maximum predicted yield of 75%, this 
system is suitable for antisolvent crystallisation. 




Milled form II raw 
material
Recrystallised form I 
from raw material


























Early Stage Process Workflow
Solvents Screening Novel Miniature Platform Development 
for Morphology Optimisation
1. Vasconcelos AT, Da Silva CC, Queiroz Júnior LHK, Santana MJ, Ferreira VS, Martins FT. Lamivudine as a nucleoside template to engineer 
DNA-like double-stranded helices in crystals. Cryst Growth Des. 2014;14(9):4691-4702. doi:10.1021/cg500786m













































































The feedback relation between the modules of the 
platform including temperature and flow control and 
the image processing.
LabVIEW front panel ensuring the automatic control and 






• Increasing numbers of HIV/AIDS infections on yearly basis 
(2.1 million new cases in 2015, UNAIDS)
• Hepatitis B infections (257 million cases globally, WHO)
• Currently FDA-approved antiretroviral therapy for the 
prevention and treatment of both viral infections (FDA).
Why the considerations for 
Lamivudine?
To the best of our knowledge, no publication yet exists on 
continuous manufacturing of stable Lamivudine form 1. The 
key research question here is:
 Translate current batch crystallisation into a 
continuous process?
 Improve the downstream process-ability by modifying 
the particle properties?
 Develop miniaturise platforms for accelerated 
process development?












 Marketed API (Epivir®)
 Unstable under 
mechanical action
 Requires water activity 
of ~ 5 - 20% Recrystallised form I wet product 
from cooling crystallisation
• Only solutions prepared at starting points of 0.6 
and 0.4 solvent mass fractions can be driven 
into a supersaturated state by the addition of 
Acetonitrile.
• Highest achievable supersaturation: 1.5. 
Maximum projected yield: 32%
• This means that the yield of the isothermal anti-
solvent crystallisation in this system is 40%
lower than a cooling crystallisation
Chemical structure 
of Lamivudine
 Metastable zone width of the binary mixtures identified for the two 
solvents screening.
 A miniature platform was developed for morphology screening and 
incorporation of the feedback control to optimize the shape and size of 
Lamivudine crystals. 
 Screening of potential solvent pairs suitable for developing continuous antisolvent 
crystallisation.
 The developed novel platform will be applied for morphology screening and incorporation of 
the feedback control to optimize the shape and size of Lamivudine crystals.
Miniaturised parallel 
screening platform
15 vials with 




*MSZW – Metastable zone width, *AS - Antisolvent
*MSMPR – Mixed-suspension, mixed-product removal
*COBC – Continuous oscillatory baffled crystalliser, 
*DoE – Design of experiment
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